Recent Updates
Recently added Catalysts
TIL Positive Sentiment Score: 70/100

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Friday, May 23, 2025 2 min read
Key Takeaway: Instil Bio and ImmuneOnco will host an investor and analyst breakfast on May 31, 2025, in Chicago. The event aims to discuss the evolving landscape of PD-(L)1xVEGF bispecific antibodies and share recent clinical trial updates. Attendees are encouraged to register in advance to secure their seats.

Market Sentiment Analysis

POSITIVE FACTORS

  • Joint event highlights collaboration between Instil Bio and ImmuneOnco.
  • Focus on innovative PD-(L)1xVEGF bispecific antibody therapies.
  • Opportunity for investors to engage with key opinion leaders.

Full Press Release Details

DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research analyst breakfast in Chicago, Illinois on Saturday, May 31, 2025 at 8:00 to 9:30 am CT adjacent to the McCormick Convention Center.
Instil and ImmuneOnco management, along with a key opinion leader in the field of immuno-oncology, will discuss the evolving PD-(L)1xVEGF bispecific antibody landscape and recent clinical trial updates from Instil and ImmuneOnco.
Investors and analysts interested in attending should register by emailing their contact information to reserve seating toinvestorrelations@instilbio.com.
About ImmuneOncoImmuneOnco is a clinical-stage biotech company focused on discovery and development of biologics to treat cancers, autoimmune diseases and metabolic diseases. With 10+ assets all originated in-house and the most advanced asset in phase III right now, ImmuneOnco is pursuing innovative therapies to improve patients’ health. For more information visitwww.immuneonco.com.
About Instil BioInstil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil's lead asset, AXN-2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors. For more information, visitwww.instilbio.com.
Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as the date hereof, and Instil disclaims any obligation to update these statements except as may be required by law.
Contacts:Investor Relations:1-972-499-3350investorrelations@instilbio.comwww.instilbio.com

Frequently Asked Questions

When is the investor breakfast hosted by Instil and ImmuneOnco?

The investor breakfast will take place on May 31, 2025, from 8:00 to 9:30 am CT.

Where will the investor breakfast be held?

The event will be held in Chicago, Illinois, adjacent to the McCormick Convention Center.

What will be discussed at the investor breakfast?

The discussion will focus on the evolving PD-(L)1xVEGF bispecific antibody landscape and clinical trial updates.

How can investors register for the event?

Interested investors should email their contact information to investorrelations@instilbio.com.

Tags: TIL Viatris Investor Conferences Healthcare Instil Bio ImmuneOnco ASCO 2025 clinical trials biopharmaceuticals
Last updated: May 23, 2025